The differences in efficacy of IL-6 inhibition and B cell-deficiency in IFN-β treated TH17-EAE may provide insights into how IFN-high and IFN-low NMOSD patients will respond to these therapies. The gene discussed is IL6; the disease is hyperinsulinemic hypoglycemia, familial, 4.